Figure Legends
Figure 1. Design of the microfluidic transfection device. (A) Photograph of the serpentine device. (B) Schematic of microfluidic chaotic-based delivery system used to transfect DNA into human myeloma cells. Briefly, cells and DNA were mixed in suspension, chaotic advection creating
vortices in inner wall that disrupt cell membranes to permit permeability and allow DNA to diffuse into cells. (C) simulation of velocity magnitude (m/ s) in chip containing U-turn channels.
Figure 2. Microscopy of myeloma cells expressing green fluorescent protein 24 hours post transfection in 2 different gene delivery systems: (A) Non-transfected cell, (B) Nucleofection, (C) Microfluidic Transfection Device.
Figure 3. Levels of EGFP protein expression in myeloma cells compared to nucleofection. (A) Representative experiment for the percent of transfected cells following microfluidic transfection reveals high GFP expression and viability compared to nucleofection. (B) Transfection efficiency in human myeloma cells transfected with various concentrations of DNA via our microfluidic device.
Figure 4. Comparison of intracellular delivery methods in mRNA and protein expression. (A) mRNA level measured by q RT-PCR of target gene 48h post transfection. The results are presented as the mean ± SD of three different experiments, p<0.001. (B) Representative percentage of myeloma cells that exhibit surface protein expression after microfluidic processing and nucleofection 48 h post transfection.